Sign in
Not yet recruitingPhase 4

Vitamin D as add-on treatment option of pneumonia and sepsis in elderly subjects (TreatViD)

Key facts

Who runs it
Azienda Ospedaliero-Universitaria Maggiore Della Carita
Where
Italy2 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
552 people, planned
Started
1 Sept 2025
Expected to end
31 Aug 2028
Type of study
Interventional
Record updated
10 September 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Age ≥ 65 years (no gender restriction)
  • Fulfillment of one of the two following diagnostic criteria: • Diagnosis of pneumonia due to a presumed infection, confirmed by chest plain radiographs or CT scan, according to the ATS/IDSA guidelines [Metlay et al., 2019; Mandell et al., 2007] (including COVID-19 related pneumonia confirmed by a RT-PCR or third-generation antigenic test) (pneumonia section of the study); • Diagnosis of sepsis (patients meeting the Third International Consensus Definitions for Sepsis; Sepsis-3 [Singer et al., 2016]) (sepsis section of the study)
  • Need for hospitalization in a non-intensive care unit (non-ICU) (hospitalization in general wards including high dependency/sub-intensive wards)
  • Serum 25(OH)D < 20 ng/ml at admission
  • Symptoms onset from no more than 10 days
  • NEWS2>2
  • Patient or his/her legal representative ability to understand, sign, and date the written authorized informed consent form

Who cannot take part

  • Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within 5 half-lives of the study drug, whichever is longer
  • History of chronic liver diseases associated to liver failure (i.e. hepatic cirrhosis CHILDB or greater)
  • Known malabsorption syndromes
  • History of nephrocalcinosis
  • Inability to tolerate or clinical conditions contraindicating oral therapy or vitamin D supplementation
  • Advanced cancer or other advanced chronic diseases with an estimated prognosis of less than 30 days
  • Known history of allergy/intolerance to cholecalciferol (vitamin D3) or any excipient used in the intervention formulation
  • Severe renal failure (GFR < 15 ml/min) or history of recurrent nephrolithiasis
  • Hypercalcemia (ionized serum calcium > 1.4 mmol/l (5.6 mg/dl) or albumin-adjusted serum calcium > 2.63 mmol/l (10.5 mg/dl))
  • History of hypercalciuria (urinary calcium excretion > 0.1 mmol/kg body weight/day (4 mg/kg body weight/day))
  • Extremely critical presentation, suggestive of immediate need for ICU admission of imminent death
  • Known sarcoidosis
  • Known primary hyperparathyroidism
  • BMI > 35 kg/m2

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim/objective of TreatViD clinical trial is to evaluate efficacy and safety of a high dose vitamin D3 (cholecalciferol) regimen in elderly patients hospitalized for pneumonia due to an infection (including COVID-19), study section 1,or sepsis, study section 2, in increasing discharge rate from hospital and/or reducing in-hospital mortality and/or in reducing laboratory markers of inflammation. To reach such goal, the proposed clinical trial is divided in two separated sections according to the underlying diagnosis at admission (pneumonia section (1) and sepsis section (2)).

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2024-515978-27-00, who can take part
Record updated
10 September 2025